» Articles » PMID: 25593119

Test-retest Reproducibility of Binding Parameters in Humans with 11C-LY2795050, an Antagonist PET Radiotracer for the κ Opioid Receptor

Overview
Journal J Nucl Med
Specialty Nuclear Medicine
Date 2015 Jan 17
PMID 25593119
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled: (11)C-LY2795050 is a new antagonist PET radioligand for the κ opioid receptor (KOR). In this study, we assessed the reproducibility of the binding parameters of (11)C-LY2795050 in healthy human subjects.

Methods: Sixteen healthy subjects (11 men and 5 women) underwent 2 separate 90-min PET scans with arterial input function and plasma free fraction (fP) measurements. The 2-tissue-compartment model and multilinear analysis-1 were applied to calculate 5 outcome measures in 14 brain regions: distribution volume (VT), VT normalized by fP (VT/fP), and 3 binding potentials (nondisplaceable binding potential, binding potential relative to total plasma concentration, and binding potential relative to free plasma concentration: BPND, BPP, BPF, respectively). Since KOR is distributed ubiquitously throughout the brain, there are no suitable reference regions. We used a fixed fraction of individual cerebellar VT value (VT,CER) as the nondisplaceable VT (VND) (VND = VT,CER/1.17). The relative and absolute test-retest variability and intraclass correlation coefficient were evaluated for the outcome measures of (11)C-LY2795050.

Results: The test-retest variability of (11)C-LY2795050 for VT was no more than 10% in any region and was 12% in the amygdala. For binding potential (BPND and BPP), the test-retest variability was good in regions of moderate and high KOR density (BPND > 0.4) and poor in regions of low density. Correction by fP (VT/fP or BPF) did not improve the test-retest performance.

Conclusion: Our results suggest that quantification of (11)C-LY2795050 imaging is reproducible and reliable in regions with moderate and high KOR density. Therefore, we conclude that this first antagonist radiotracer is highly useful for PET studies of KOR.

Citing Articles

Strategies for the Production of [C]LY2795050 for Clinical Use.

Kaur T, Shao X, Horikawa M, Sharninghausen L, Preshlock S, Brooks A Org Process Res Dev. 2023; 27(2):373-381.

PMID: 36874204 PMC: 9983641. DOI: 10.1021/acs.oprd.2c00388.


Low-Dose Augmentation With Buprenorphine for Treatment-Resistant Depression: A Multisite Randomized Controlled Trial With Multimodal Assessment of Target Engagement.

Lee H, Blumberger D, Lenze E, Anderson S, Barch D, Black K Biol Psychiatry Glob Open Sci. 2022; 2(2):127-135.

PMID: 36325158 PMC: 9616305. DOI: 10.1016/j.bpsgos.2021.09.003.


The opioid system in depression.

Jelen L, Stone J, Young A, Mehta M Neurosci Biobehav Rev. 2022; 140:104800.

PMID: 35914624 PMC: 10166717. DOI: 10.1016/j.neubiorev.2022.104800.


The molecular neurobiology and neuropathology of opioid use disorder.

Blackwood C, Cadet J Curr Res Neurobiol. 2022; 2.

PMID: 35548327 PMC: 9090195. DOI: 10.1016/j.crneur.2021.100023.


Rapid-Onset Anti-Stress Effects of a Kappa-Opioid Receptor Antagonist, LY2795050, Against Immobility in an Open Space Swim Paradigm in Male and Female Mice.

Baynard C, Prisinzano T, Butelman E Front Pharmacol. 2021; 12:775317.

PMID: 34880762 PMC: 8645979. DOI: 10.3389/fphar.2021.775317.


References
1.
Mello N, Negus S . Interactions between kappa opioid agonists and cocaine. Preclinical studies. Ann N Y Acad Sci. 2000; 909:104-32. DOI: 10.1111/j.1749-6632.2000.tb06678.x. View

2.
Caravaggio F, Raitsin S, Gerretsen P, Nakajima S, Wilson A, Graff-Guerrero A . Ventral striatum binding of a dopamine D2/3 receptor agonist but not antagonist predicts normal body mass index. Biol Psychiatry. 2013; 77(2):196-202. PMC: 3783412. DOI: 10.1016/j.biopsych.2013.02.017. View

3.
Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N . Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage. 2002; 15(1):273-89. DOI: 10.1006/nimg.2001.0978. View

4.
Ichise M, Liow J, Lu J, Takano A, Model K, Toyama H . Linearized reference tissue parametric imaging methods: application to [11C]DASB positron emission tomography studies of the serotonin transporter in human brain. J Cereb Blood Flow Metab. 2003; 23(9):1096-112. DOI: 10.1097/01.WCB.0000085441.37552.CA. View

5.
De Lanerolle N, Williamson A, Meredith C, Kim J, Tabuteau H, Spencer D . Dynorphin and the kappa 1 ligand [3H]U69,593 binding in the human epileptogenic hippocampus. Epilepsy Res. 1997; 28(3):189-205. DOI: 10.1016/s0920-1211(97)00044-2. View